Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Samsara BioCapital
Deal Size : $20.0 million
Deal Type : Series B Financing
Palladio Completes $20 Million Series B Financing
Details : Proceeds from the financing will fund Palladio’s Phase 3 ALERT Study and advance operations.
Brand Name : VPA-985
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 25, 2020
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Samsara BioCapital
Deal Size : $20.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?
Reset All
